Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Asuragen

Asuragen
2005 FOUNDED
PRIVATE STATUS
101-200 EMPLOYEES
Series C LATEST DEAL TYPE
$7.5M LATEST DEAL AMOUNT
5 INVESTORS
Description

Developer of molecular diagnostic products intended to change the way patients are treated in genetics and oncology. The company's molecular diagnostic products have high quality, sensitivity and simplicity to deliver true precision medicine, enabling medical professionals to understand critical clinical situations.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Diagnostic Equipment
Primary Office
  • 2150 Woodward Street
  • Suite 100
  • Austin, TX 78744
  • United States

+1 (512) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Asuragen’s full profile, request a free trial.

Asuragen Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series C) 20-Mar-2013 $7.5M 000.00 00000 Completed Generating Revenue
5. Grant 30-Mar-2012 00.00 000.00 Completed Generating Revenue
4. Later Stage VC (Series C) 11-Aug-2011 000 000.00 000.00 Completed Generating Revenue
3. Grant 08-Oct-2008 00.00 000.00 Completed Startup
2. Early Stage VC (Series B) 10-Dec-2007 $18.5M $67.4M 000.00 Completed Startup
1. Early Stage VC (Series A) 01-Jun-2006 $48.9M $48.9M 000.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Asuragen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series B 00,000,000 00.000000 00.0 00.0 00 00.0 00.000
Series A 48,895,000 $0.001000 $1 $1 1x $1 55.48%
To view this company’s complete Cap Table, request access »

Asuragen Competitors (18)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ELITech Group Private Equity-Backed Puteaux, France 000 000.00 000000000000
00000 00000000 Private Equity-Backed Aliso Viejo, CA 000 00000 000000&0 00000
000000 000000000 Formerly PE-Backed Codolet, France 000 000000&0
000000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 0000000000 0 00000
000000 00000000 Venture Capital-Backed Buffalo, NY 00.000 0000000000 0 00.000
To view this company’s complete list of competitors, request access »

Asuragen Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 01-Jan-2009 00000 00000 00 000 Biotechnology 0000000 0000000 00.0
Mirna Therapeutics 04-Apr-2008 Seed Round 000 Biotechnology 0000000 0000000 00.0
To view this company’s complete investment and acquisition history, request access »

Asuragen Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000 000000000000 01-Jan-2009 00000 00000 00 000 Completed
  • 00000000
Mirna Therapeutics 04-Apr-2008 Seed Round 000 Completed
To view this company’s complete exits history, request access »

Asuragen Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
State Of Texas Real Estate Fund Real Estate 000 0000 000000 0
Merck Global Health Innovation Fund Corporate Venture Capital Minority 000 0000 000000 0
PTV Healthcare Capital Venture Capital Minority 000 0000 000000 0
Southwest Middle Market M&A Merchant Banking Firm Minority 000 0000 000000 0
Telegraph Hill Partners Venture Capital Minority 000 0000 000000 0

Asuragen Executive Team (18)

Name Title Board
Seat
Contact
Info
Matthew McManus MD Chief Executive Officer, President & Director
Lynne Hohlfeld Chief Financial Officer & Senior Vice President, Corporate Development
Matthew Winkler Ph.D Founder and Chairman
Colin Hill Senior Vice President Commercial Operations
Bernard Andruss Ph.D Senior Vice President, Operations

9 Former Executives

You’re viewing 5 of 18 executives. Get the full list »

Asuragen Board Members (10)

Name Representing Role Since Contact
Info
Christopher Earl Ph.D Self Board Member 000 0000
David Rubin Ph.D Merck & Co. Board Member 000 0000
David Sargent Self Board Member 000 0000
Deval Lashkari Ph.D Telegraph Hill Partners Board Member 000 0000
J. Matthew Mackowski Telegraph Hill Partners Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 10 board members. Get the full list »